Karuna Therapeutics, Inc. announced the appointment of Will Kane as chief commercial officer (CCO), effective February 6, 2023. Mr. Kane brings more than three decades of experience in the pharmaceutical industry. He's held senior level commercial positions at leading biopharma companies, Allergan, Pfizer, and Sepracor (now Sunovion Pharmaceuticals), and was an integral part of launching several successful brands, including CELEBREX® for the treatment of arthritis, NAMZARIC®?

for Alzheimer's disease, VRAYLAR® for the treatment of schizophrenia and bipolar disorder, and UBRELVY™, the first oral calcitonin gene-related peptide (CGRP) for the acute treatment of migraine. Most recently, he was the executive vice president and chief commercial officer at BioXcel Therapeutics. Mr. Kane holds a B.A. in Government from Connecticut College and an M.B.A. from the Wharton School at the University of Pennsylvania.